A curcumin analog, GO-Y078, effectively inhibits angiogenesis through actin disorganization

Anti-Cancer Agents in Medicinal Chemistry

Volumn 16, Issue 5, 2016, Pages 633-647

  Sugiyama, Shunsuke ^a   Yoshino, Yuki ^a   Kuriyama, Sei ^b   Inoue, Masahiro ^b   Komine, Keigo ^b   Otsuka, Kazunori ^b   Kohyama, Aki ^a   Yamakoshi, Hiroyuki ^a   Ishioka, Chikashi ^a   Tanaka, Masamitsu ^b   Iwabuchi, Yoshiharu ^a   Shibata, Hiroyuki ^b  

^a TOHOKU UNIVERSITY   (Japan)

^b AKITA UNIVERSITY   (Japan)

Author keywords

Actin; Angiogenesis inhibitors; Curcumin; Endothelial cells; Vascular endothelial growth factor a

Indexed keywords

ACTIN; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN RECEPTOR; B RAF KINASE; CASPASE 3; CURCUMIN; F ACTIN; FOCAL ADHESION KINASE; GELATIN; GELATINASE A; GO Y078; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE; NESTIN; PHOSPHOLIPASE C GAMMA; PROTEIN KINASE B; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VINCULIN; GO-Y078; VASCULOTROPIN;

ACTIN POLYMERIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL INVASION ASSAY; CELL MOTILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA CONTENT; EMBRYO; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IC50; IMMUNOHISTOCHEMISTRY; MALE; MIGRATION INHIBITION; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TADPOLE; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; XENOPUS LAEVIS; ZYMOGRAPHY; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; STRUCTURE ACTIVITY RELATION;

ACTINS; ANIMALS; APOPTOSIS; CELL LINE; CELL PROLIFERATION; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HUMANS; MOLECULAR STRUCTURE; NEOVASCULARIZATION, PATHOLOGIC; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOPUS LAEVIS;

EID: 84964037860     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520615666151013125559     Document Type: Article

References (29)

1. Kazazi-Hyseni, F.; Beijnen, J.H.; Schellens, J.H. Bevacizumab. Oncologist, 2010, 15, 819-825.
2. Gaya, A.; Tse, V. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev., 2012, 38, 484-493.
3. Kim, A.; Balis, F.M.; Widemann, B.C. Sorafenib and sunitinib. Oncologist, 2009, 14, 800-805.
4. Gupta, S.C.; Prasad, S.; Kim, J.H.; Patchva, S.; Webb, L.J.; Priyadarsini, I.K.; Aggarwal, B.B. Multitargeting by curcumin as revealed by molecular interaction studies. Nat. Prod. Rep., 2011, 28, 1937-1955.
5. Yoysungnoen, P.; Wirachwong, P.; Changtam, C.; Suksamrarn, A.; Patumraj, S. Anti-cancer and anti-angiogenic effects of curcumin and tetrahydrocurcumin on implanted hepatocellular carcinoma in nude mice. World J. Gastroenterol., 2008, 14, 2003-2009.
6. Gupta, S.C.; Patchva, S.; Aggarwal, B.B. Therapeutic roles of curcumin: Lessons learned from clinical trials. AAPS J., 2013, 15, 195-218.
7. Ohori, H.; Yamakoshi, H.; Tomizawa, M.; Shibuya, M.; Kakudo, Y.; Takahashi, A.; Takahashi, S.; Kato, S.; Suzuki, T.; Ishioka, C.; Iwabuchi, Y.; Shibata, H. Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol. Cancer Ther., 2006, 5, 2563-2571.
8. Kudo, C.; Yamakoshi, H.; Sato, A.; Nanjo, H.; Ohori, H.; Ishioka, C.; Iwabuchi, Y.; Shibata, H. Synthesis of 86 species of 1,5-diaryl-3-oxo-1,4-pentadienes analogs of curcumin can yield a good lead in vivo. BMC Pharmacol., 2011, 11, 4.
9. Sato, A.; Kudo, C.; Yamakoshi, H.; Uehara, Y.; Ohori, H.; et al. Curcumin analog GO-Y030 is a novel inhibitor of IKKβ that suppresses NF-κB signaling and induces apoptosis. Cancer Sci., 2011, 102, 1045-1051.
10. Lin, L.; Liu, Y.; Li, H.; Li, PK.; Fuchs, J.; Shibata, H.; Iwabuchi, Y.; Lin, J. Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030. Br. J. Cancer, 2011, 105, 212-220.
11. Kudo, C.; Yamakoshi, H.; Sato, A.; Ohori, H.; Ishioka, C.; Iwabuchi, Y.; Shibata, H. Novel curcumin analogs, GO-Y030 and GO-Y078, are multi-targeted agents with enhanced abilities for multiple myeloma. Anticancer Res., 2011, 31, 3719-3726.
12. Shibata, H.; Yamakoshi, H.; Sato, A.; Ohori, H.; Kakudo, Y.; Kudo, C.; Takahashi, Y.; Watanabe, M.; Takano, H.; Ishioka, C.; Noda, T.; Iwabuchi, Y. Newly synthesized curcumin analog has improved potential to prevent colorectal carcinogenesis in vivo. Cancer Sci., 2009, 100, 956-960.
13. Yamakoshi, H.; Kanoh, N.; Kudo, C.; Sato, A.; Ueda, K.; Muroi, M.; Kon, S.; Satake, M.; Ohori, H.; Ishioka, C.; Oshima, Y.; Osada, H.; Chiba, N.; Shibata, H.; Iwabuchi, Y. KSRP/FUBP2 is a Binding Protein of GO-Y086, a Cytotoxic Curcumin Analogue. ACS Med. Chem. Lett., 2010, 1, 273-276.
14. Uehara, Y.; Inoue, M.; Fukuda, K.; Yamakoshi, H.; Hosoi, Y.; Kanda, H.; Oshima, M.; Iwabuchi. Y.; Shibata, H.; Inhibition of β- catenin and STAT3 with a curcumin analog suppresses gastric carcinogenesis in vivo. Gastric Cancer, 2015, 18(4), 774-783.
15. Jia, Y.; Wu, S.L.; Isenberg, J.S.; Dai, S.; Sipes, J.M.; Field, L.; Zeng, B.; Bandle, R.W.; Ridnour, L.A.; Wink, D.A.; Ramchandran, R.; Karger, B.L.; Roberts, D.D. Thiolutin inhibits endothelial cell adhesion by perturbing Hsp27 interactions with components of the actin and intermediate filament cytoskeleton. Cell Stress Chaperones, 2010, 15, 165-181.
16. Nambotin, S.B.; Tomimaru, Y.; Merle, P.; Wands, J.R.; Kim. M.; Functional consequences of WNT3/Frizzled7-mediated signaling in non-transformed hepatic cells. Oncogenesis, 2012, 1, e31.
17. Kälin, R.E.; Bänziger-Tobler, N.E.; Detmar, M.; Brändli, A.W. An in vivo chemical library screen in Xenopus tadpoles reveals novel pathways involved in angiogenesis and lymphangiogenesis. Blood, 2009, 114, 1110-1122.
18. Matsumoto, T.; Mugishima, H. Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis. J. Atheroscler. Thromb., 2006, 13, 130-135.
19. Lamalice, L.; Le Boeuf, F.; Huot, J. Endothelial cell migration during angiogenesis. Circ. Res., 2007, 100, 782-794.
20. Keezer, S.M.; Ivie, S.E.; Krutzsch, H.C.; Tandel, A.; Libutti, S.K.; Roberts, D.D. Angiogenesis inhibitors target the endothelial cell cytoskeleton through altered regulation of heat shock protein 27 and cofilin. Cancer Res., 2003, 63, 6405-6412.
21. Kim, J.; Kang, D.; Sun, B.K.; Kim, J.H.; Song, J.J. TRAIL/ MEKK4/p38/HSP27/Akt survival network is biphasically modulated by the Src/CIN85/c-Cbl complex. Cell Signal., 2013, 25, 372-379.
22. Leyon, P.V.; Kuttan, G. Studies on the role of some synthetic curcuminoid derivatives in the inhibition of tumour specific angiogenesis. J .Exp. Clin. Cancer Res., 2003, 22, 77-83.
23. Jankun, J.; Aleem, A.M.; Malgorzewicz, S.; Szkudlarek, M.; Zavodszky, M.I.; Dewitt, D.L.; Feig, M.; Selman, S.H.; Skrzypczak-Jankun, E. Synthetic curcuminoids modulate the arachidonic acid metabolism of human platelet 12-lipoxygenase and reduce sprout formation of human endothelial cells. Mol. Cancer Ther., 2006, 5, 1371-1382.
24. Lin, L.; Hutzen, B.; Zuo, M.; Ball. S.; Deangelis, S.; Foust, E.; Pandit, B.; Ihnat, M.A.; Shenoy, S.S.; Kulp, S.; Li, P.K.; Li, C.; Fuchs, J.; Lin, J. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res., 2010, 70, 2445-4254.
25. Chen, C.1.; Liu, Y.; Chen, Y.; Xu, J. C086, a novel analog of curcumin, induces growth inhibition and down-regulation of NFon of NFsuppressive activity xenograft tumors. Cancer Biol. Ther., 2011, 12, 797-807.
26. Liu, H.; Liang, Y.; Wang, L.; Tian, L.; Song, R.; Han, T.; Pan, S.; Liu, L.; In vivo and in vitro suppression of hepatocellular carcinoma by EF24, a curcumin analog. PLoSOne, 2012, 7, e48075.
27. Kumar, B.; Yadav, A.; Hideg, K.; Kuppusamy, P.; Teknos, T.N.; Kumar, P.; A novel curcumin analog (H-4073) enhances the therapeutic efficacy of cisplatin treatment in head and neck cancer. PLoS One, 2014, 9, e93208.
28. Brooks, A.N.; Kilgour, E.; Smith, P.D. Molecular pathways: Fibroblast growth factor signaling: A new therapeutic opportunity in cancer. Clin. Cancer Res., 2012, 18, 1855-1862.
29. Gherardi, E.; Birchmeier, W.; Birchmeier, C.; Vande, W.G. Targeting MET in cancer: Rationale and progress. Nat. Rev. Cancer, 2012, 12, 89-103.